BPH Global Ltd

Renewal of China Tobacco Agreements

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company has entered into two (2) new agreements with the China Tobacco group for the sale and distribution of bird’s nest products via China Tobacco’s outlets in the City of Guangzhou in China for calendar year 2024 (2024 Agreements).


Highlights

  • Sales and distribution agreements with China Tobacco renewed for 2024.
  • Ongoing sales and distribution activities branded with BP8 Group brand names.
  • Potential to expand sales and distribution footprint.
New China Tobacco Sales and Distribution Agreements

The 2024 Agreements are effectively a renewal of the two (2) sales and distribution agreements from 2023 between the Company’s now wholly owned subsidiary Foshan Gedishi Biotechnology Co Ltd (Foshan) and two (2) wholly owned subsidiaries of China Tobacco based in Guangzhou City in the Province of Guangdong (2023 Agreements). The two wholly owned subsidiaries are Guangzhou Gold Leaves Franchise Co Ltd (Golden Leaves) and Guangzhou City Twenty Sticks Commercial Franchise Co Ltd (Twenty Sticks).

The principal terms of the 2024 Agreements include:

  • commencement date 1 January 2024;
  • term 12 months;
  • products to be supplied:
    • pure bird’s nest 50g box;
    • pure bird’s nest 100g box; and
    • bird’s nest drink - each box contains 3 bottles with 1.5g bird nest content; and
  • products to be sold in China Tobacco outlets in the Guangzhou Province of China.

Commencement of sales and distribution operations

The Company is also pleased to announce that, in the lead up period prior to Chinese New Year, Foshan has commenced sales and distribution operations in China:

  • pursuant to the 2024 Agreements in the Guangzhou Province; and
  • directly on Douyin (the mainland Chinese counterpart of TikTok).

Foshan supplies bird’s nest products to both Golden Leaves and Twenty Sticks at agreed wholesale prices. Golden Leaves and Twenty Sticks determine the retail prices of the bird’s nest products supplied by Foshan.

Golden Leaves and Twenty Sticks operate “China Tobacco” branded retail outlets in Guangzhou City including high-end retail outlets. Foshan currently supplies bird’s products to over 100 (in aggregate) Golden Leaves’ and Twenty Sticks’ retail outlets in Guangzhou City including high-end retail outlets. The Company’s bird’s next products are also stored in China Tobacco warehouses in Guangzhou.

The Company’s bird’s nest products for sale in a China Tobacco Guangzhou City outlet

The Company’s bird’s nest products for sale in a China Tobacco Guangzhou City outlet

Chinese New Year commences on Saturday, 10 February 2024 and continues for two weeks until Saturday 24 February. Raw bird’s nest and bird’s nest infused products are popular gifts in the Chinese New Year period. The Company will inform the market regarding the initial sales achieved in the trading period commencing in January through to the end of the Chinese New Year period (Initial Trading Period) after the conclusion of the Chinese New Year period.


Click here for the full ASX Release

This article includes content from BPH Global Ltd, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BP8:AU
The Conversation (0)
  BPH Global Ltd

Half Yearly Report and Accounts

BPH Global Ltd (ASX: BP8) (Company) is pleased to present its Half Year Report.


Keep reading...Show less

AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO

Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio the newest in its global operations network and the most advanced facility to date.

"Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway , chairman and chief executive officer at Amgen. "As part of Amgen's global biomanufacturing network, Amgen Ohio will play an important role in helping us address serious disease around the world with our innovative biomedicines."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim in Early 2025

Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim in Early 2025

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey. A recent exclusive video interview featuring Dr. Geraldine Deliencourt-Godefroy, Sirona's Chief Scientific Officer, has been released by the Investing News Network. In this interview, Dr. Deliencourt-Godefroy unveils Sirona's ambitious plans to introduce its innovative anti-aging product, GlycoProteMimTM, to the markets of North America and Europe in early 2025.

The interview provides an insightful look into the revolutionary potential of GlycoProteMim in the anti-aging sector. Viewers can access the full interview on the Investing News Network's website through this link: investingnews.com/sirona-biochem-eyes-2025-launch-of-new-anti-aging-product/

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE

Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon executive vice president of Global Commercial Operations at Amgen, Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, Vikram Karnani executive vice president of Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, and Paul Burton senior vice president and chief medical officer at Amgen, will participate in the conference call. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Provides Update on Loan

Sirona Biochem Provides Update on Loan

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") announce that, further to its news release on January 29, 2024, it has entered into an amendment to the demand grid promissory note dated September 22, 2023 (the " Amended Note ") with 0906462 B.C. Ltd. (the " Lender "). The Amended Note evidences a loan in the aggregate principal amount of up to $1,000,000 (the " Loan "). Pursuant to the terms and conditions of the Amended Note:

(a)   the Loan is repayable on demand by the Lender at any time following the one-year anniversary of the date of the applicable advance;

(b)   the Loan bears interest at a rate of 12% per annum, calculated yearly not in advance; and

(c)   the Company has agreed to, subject to TSX Venture Exchange approval (" TSXV Approval "), issue the Lender 450,000 common shares in the capital of the Company (" Bonus Shares ") at a price of $0.12 per Bonus Share, as consideration for the risks taken by the Lender in providing the Company the Loan.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×